PharmaResearch\u00a0signed an agreement on June 30, local time, to\u00a0acquire\u00a0CG USA, a cosmetics OEM and ODM manufacturer, as demand for REJURAN Cosmetics continues to grow in the United States.\u00a0<\/p>\n Based in California, CG USA is a cosmetics OEM and ODM manufacturer with capabilities across product planning, formula development, manufacturing, filling, packaging,\u00a0and quality control. The company holds a cosmetics manufacturing license and\u00a0operates\u00a0an FDA-registered facility with a quality management system aligned\u00a0with current good manufacturing practice, or\u00a0cGMP,\u00a0standards. Its manufacturing infrastructure also supports production of\u00a0over-the-counter\u00a0(OTC) products.\u00a0<\/p>\n PharmaResearch\u00a0decided to pursue the acquisition to respond more stably to growing demand for REJURAN Cosmetics, driven in part by its Sephora launch and expanding Amazon channel.\u00a0Until now, the company has supplied the U.S. market with products manufactured in Korea. Through the acquisition of CG USA,\u00a0PharmaResearch\u00a0will secure a local manufacturing base, creating a foundation to improve supply chain efficiency and market responsiveness across production,\u00a0logistics\u00a0and distribution.\u00a0<\/p>\n Building on this, the company plans to strengthen supply stability in North America while accelerating its localization strategy across the Americas to support future expansion into Canada, broader North\u00a0America\u00a0and South America.\u00a0<\/p>\n REJURAN Cosmetics is\u00a0PharmaResearch’s\u00a0premium derma cosmetics brand, developed from the company’s regenerative medicine technology. Built around DOT\u2122 c-PDRN\u00ae, the company’s patented cosmetic-grade PDRN ingredient,\u00a0the brand has expanded its U.S.\u00a0presence through\u00a0online and offline retail channels, including Sephora and Amazon. REJURAN Cosmetics is also scheduled to enter Canada in the second half of the year, adding momentum to\u00a0PharmaResearch’s\u00a0broader North American expansion.\u00a0<\/p>\n “The acquisition of CG USA is a strategic decision to strengthen supply stability and build a stronger foundation for business expansion in North America,” said Ji Hoon Sohn, CEO of\u00a0PharmaResearch. “Through this acquisition,\u00a0PharmaResearch\u00a0will secure a local production base to support its growth in North America, while also gaining the potential to expand its ODM business in the U.S. over the mid to long term.”\u00a0<\/p>\n Sohn added, “CG USA’s FDA-registered facility and OTC production capabilities make this acquisition meaningful not only for cosmetics, but also as a foundation for expanding into over-the-counter production. Based on local production capabilities and quality infrastructure, we will continue to strengthen the competitiveness of our global derma cosmetics business.”\u00a0<\/p>\n A CG USA representative said,\u00a0“We are pleased to partner with\u00a0PharmaResearch\u00a0at an important stage in the growth of REJURAN Cosmetics. We look forward to supporting the brand’s expansion by bringing together CG USA’s manufacturing capabilities and\u00a0PharmaResearch’s\u00a0expertise.”\u00a0<\/p>\n Cosmo Group Inc.\u00a0advised on the acquisition. Financial terms were not\u00a0disclosed.\u00a0<\/p>\n About\u00a0PharmaResearch:<\/b>\u00a0<\/p>\n PharmaResearch\u00a0is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. Its diverse portfolio includes medicines, medical devices, cosmetics, and\u00a0health\u00a0supplements, all\u00a0leveraging\u00a0the core ingredients – DOT\u2122 PDRN and DOT\u2122 PN – which are protected by multiple patents.\u00a0PharmaResearch\u00a0is headquartered in Gangneung-si, Gangwon-do, South Korea, and\u00a0has a\u00a0U.S. subsidiary\u00a0located\u00a0in Costa Mesa, California, United States.\u00a0<\/p>\n![\"Representatives](\"https:\/\/mma.prnasia.com\/media2\/3002845\/photo.jpg?p=medium600\" "\\"Representatives")
<\/a>
Representatives from PharmaResearch and CG USA pose for a group photo following the signing of the acquisition agreement.<\/span><\/p>\n<\/div>\n